First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) - Join Clinical Trial NCTNCT06351592
How to Join This Clinical Trial - NCTNCT06351592
Learn how to participate in this PHASE1 trial studying an investigational therapy for Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene. This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE1 - Early safety study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT06351592 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 13 locations. Find a study site near you:
Clinical Research Site
Concord, New South Wales 2139 - Australia
Status: RECRUITING
Clinical Research Site
Birtinya, Queensland 4575 - Australia
Status: RECRUITING
Clinical Research Site
Edmonton, Alberta T6G 2G3 - Canada
Status: RECRUITING
Clinical Research Site
London, Ontario N6A 5A5 - Canada
Status: RECRUITING
Clinical Research Site
Toronto, Ontario M4N3M5 - Canada
Status: RECRUITING
Clinical Research Site
Montreal, Quebec H3A 2B4 - Canada
Status: RECRUITING
Clinical Research Site
Sapporo, Hokkaido 060-8648 - Japan
Status: RECRUITING
Clinical Research Site
Tokushima-shi, Tokusima 770-0042 - Japan
Status: RECRUITING
Clinical Research Site
Ota-ku, Tokyo 143-8541 - Japan
Status: RECRUITING
Clinical Research Site
Kyoto, 606-8507 - Japan
Status: RECRUITING
And 3 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE1 clinical trial for Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships